US 12,263,155 B2
Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
Tom Spector, Chapel Hill, NC (US); Jeremy Ford, Norwell, MA (US); and Thomas A. Krenitsky, Chapel Hill, NC (US)
Assigned to Remedi, Inc., Norwell, MA (US)
Filed by Remedi, Inc., Norwell, MA (US)
Filed on Mar. 25, 2024, as Appl. No. 18/616,046.
Application 18/616,046 is a continuation of application No. PCT/US2023/080419, filed on Nov. 17, 2023.
Claims priority of provisional application 63/472,532, filed on Jun. 12, 2023.
Claims priority of provisional application 63/426,266, filed on Nov. 17, 2022.
Prior Publication US 2024/0285578 A1, Aug. 29, 2024
Int. Cl. A61K 31/39 (2006.01); A61K 31/4045 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/39 (2013.01) [A61K 31/4045 (2013.01); A61P 25/24 (2018.01)] 19 Claims
OG exemplary drawing
 
1. A pharmaceutical composition or kit of parts, useful to treat a mental health disorder in a human, comprising therapeutically effective amounts of:
a) a compound having the formula:

OG Complex Work Unit Chemistry
(CX157), or a pharmaceutically acceptable salt thereof; and
b) N,N-dimethyltryptamine (DMT), or a pharmaceutically acceptable salt thereof;
wherein the DMT is formulated for oral administration.